Mesalazine alters fecal bacterial profiles in diarrhea-predominant IBS
The latest issue of Alimentary Pharmacology & Therapeutics finds that mesalazine alters fecal bacterial profiles, but not mucosal proteolytic activity in diarrhoea-predominant irritable bowel syndrome.
fiogf49gjkf04
Imbalances in gut luminal bacteria may contribute to the pathogenesis of irritable bowel syndrome
Our site uses cookies to improve your experience.You can find out more about our use of cookies in our standard cookie policy, including instructions on how to reject and delete cookies if you wish to do so.
By continuing to browse this site you agree to us using cookies as described in our
standard cookie policy .